Denali Therapeutics IncNASDAQ:DNLI
- LAST PRICE28.6600
- TODAY'S CHANGE (%)0.4400 (1.5592%)
- Bid / Lots27.7200/ 3
- Ask / Lots29.1000/ 1
- Open / Previous Close28.5100 / 28.2200
- Day Range
- 52 Week Range
- Volume360,601
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNLI |
|---|---|---|
| 09:32 ET | 8730 | 28.5 |
| 09:34 ET | 100 | 28.62 |
| 09:36 ET | 300 | 28.535 |
| 09:38 ET | 1548 | 28.565712 |
| 09:41 ET | 1100 | 28.8799 |
| 09:43 ET | 510 | 28.765 |
| 09:45 ET | 500 | 28.93 |
| 09:48 ET | 10941 | 28.85 |
| 09:50 ET | 1699 | 28.94 |
| 09:52 ET | 1661 | 28.95 |
| 09:54 ET | 600 | 28.88 |
| 09:56 ET | 1000 | 28.75 |
| 09:57 ET | 100 | 28.75 |
| 10:01 ET | 1360 | 28.7 |
| 10:03 ET | 1100 | 28.715 |
| 10:06 ET | 200 | 28.75 |
| 10:08 ET | 200 | 28.7672 |
| 10:10 ET | 400 | 28.62 |
| 10:12 ET | 100 | 28.58 |
| 10:15 ET | 100 | 28.65 |
| 10:17 ET | 500 | 28.76 |
| 10:21 ET | 400 | 28.765 |
| 10:24 ET | 600 | 28.69 |
| 10:26 ET | 600 | 28.58 |
| 10:30 ET | 200 | 28.57 |
| 10:33 ET | 1000 | 28.575 |
| 10:35 ET | 420 | 28.6 |
| 10:37 ET | 300 | 28.66 |
| 10:42 ET | 100 | 28.61 |
| 10:44 ET | 147 | 28.63 |
| 10:48 ET | 100 | 28.66 |
| 10:50 ET | 100 | 28.645 |
| 10:51 ET | 300 | 28.73 |
| 10:53 ET | 900 | 28.765 |
| 10:55 ET | 300 | 28.736 |
| 10:57 ET | 649 | 28.75 |
| 11:00 ET | 100 | 28.775 |
| 11:02 ET | 100 | 28.81 |
| 11:04 ET | 1436 | 28.75 |
| 11:06 ET | 1000 | 28.69 |
| 11:08 ET | 500 | 28.68 |
| 11:09 ET | 100 | 28.69 |
| 11:11 ET | 731 | 28.725 |
| 11:15 ET | 623 | 28.615 |
| 11:18 ET | 700 | 28.58 |
| 11:20 ET | 600 | 28.52 |
| 11:22 ET | 3200 | 28.5744 |
| 11:24 ET | 300 | 28.52 |
| 11:26 ET | 300 | 28.54 |
| 11:27 ET | 400 | 28.5575 |
| 11:29 ET | 100 | 28.535 |
| 11:31 ET | 1639 | 28.54 |
| 11:36 ET | 600 | 28.55 |
| 11:38 ET | 1300 | 28.47 |
| 11:40 ET | 200 | 28.46 |
| 11:42 ET | 800 | 28.45 |
| 11:47 ET | 200 | 28.51 |
| 11:51 ET | 300 | 28.42 |
| 11:54 ET | 200 | 28.47 |
| 11:56 ET | 100 | 28.49 |
| 11:58 ET | 800 | 28.48 |
| 12:00 ET | 300 | 28.48 |
| 12:02 ET | 200 | 28.51 |
| 12:05 ET | 335 | 28.51 |
| 12:09 ET | 100 | 28.51 |
| 12:12 ET | 200 | 28.51 |
| 12:14 ET | 513 | 28.55 |
| 12:20 ET | 200 | 28.55 |
| 12:21 ET | 100 | 28.56 |
| 12:25 ET | 900 | 28.48 |
| 12:27 ET | 348 | 28.49 |
| 12:30 ET | 100 | 28.49 |
| 12:32 ET | 300 | 28.505 |
| 12:38 ET | 300 | 28.54 |
| 12:39 ET | 100 | 28.59 |
| 12:41 ET | 1100 | 28.56 |
| 12:43 ET | 300 | 28.585 |
| 12:45 ET | 700 | 28.61 |
| 12:48 ET | 100 | 28.62 |
| 12:54 ET | 200 | 28.57 |
| 12:56 ET | 100 | 28.61 |
| 12:59 ET | 500 | 28.555 |
| 01:03 ET | 100 | 28.54 |
| 01:06 ET | 200 | 28.56 |
| 01:08 ET | 1572 | 28.5975 |
| 01:10 ET | 320 | 28.61 |
| 01:12 ET | 200 | 28.63 |
| 01:14 ET | 3003 | 28.7 |
| 01:15 ET | 709 | 28.655 |
| 01:17 ET | 246 | 28.655 |
| 01:19 ET | 100 | 28.66 |
| 01:21 ET | 1000 | 28.61 |
| 01:24 ET | 100 | 28.58 |
| 01:26 ET | 100 | 28.58 |
| 01:30 ET | 500 | 28.53 |
| 01:32 ET | 200 | 28.485 |
| 01:33 ET | 1400 | 28.55 |
| 01:35 ET | 300 | 28.54 |
| 01:37 ET | 100 | 28.54 |
| 01:42 ET | 1850 | 28.515 |
| 01:44 ET | 200 | 28.53 |
| 01:46 ET | 747 | 28.515 |
| 01:48 ET | 200 | 28.515 |
| 01:51 ET | 676 | 28.48 |
| 01:53 ET | 200 | 28.45 |
| 01:55 ET | 100 | 28.47 |
| 01:57 ET | 500 | 28.45 |
| 02:00 ET | 200 | 28.455 |
| 02:02 ET | 100 | 28.445 |
| 02:04 ET | 200 | 28.41 |
| 02:06 ET | 200 | 28.41 |
| 02:08 ET | 100 | 28.39 |
| 02:09 ET | 100 | 28.42 |
| 02:11 ET | 100 | 28.44 |
| 02:15 ET | 400 | 28.39 |
| 02:20 ET | 200 | 28.42 |
| 02:22 ET | 294 | 28.43 |
| 02:24 ET | 100 | 28.43 |
| 02:26 ET | 1457 | 28.47 |
| 02:27 ET | 200 | 28.49 |
| 02:33 ET | 550 | 28.44 |
| 02:36 ET | 200 | 28.48 |
| 02:38 ET | 1422 | 28.465 |
| 02:40 ET | 200 | 28.44 |
| 02:42 ET | 200 | 28.45 |
| 02:44 ET | 300 | 28.48 |
| 02:45 ET | 400 | 28.46 |
| 02:47 ET | 100 | 28.48 |
| 02:49 ET | 500 | 28.46 |
| 02:51 ET | 100 | 28.46 |
| 02:54 ET | 1592 | 28.52 |
| 02:56 ET | 400 | 28.5 |
| 02:58 ET | 500 | 28.515 |
| 03:00 ET | 1029 | 28.52 |
| 03:02 ET | 300 | 28.48 |
| 03:03 ET | 100 | 28.49 |
| 03:07 ET | 1100 | 28.51 |
| 03:09 ET | 241 | 28.525 |
| 03:12 ET | 600 | 28.5 |
| 03:14 ET | 100 | 28.49 |
| 03:16 ET | 100 | 28.48 |
| 03:18 ET | 404 | 28.48 |
| 03:20 ET | 100 | 28.5 |
| 03:21 ET | 200 | 28.5 |
| 03:23 ET | 1900 | 28.52 |
| 03:25 ET | 100 | 28.49 |
| 03:27 ET | 451 | 28.47 |
| 03:30 ET | 219 | 28.485 |
| 03:32 ET | 700 | 28.445 |
| 03:34 ET | 600 | 28.425 |
| 03:36 ET | 1027 | 28.49 |
| 03:38 ET | 500 | 28.47 |
| 03:39 ET | 100 | 28.48 |
| 03:41 ET | 735 | 28.46 |
| 03:43 ET | 700 | 28.43 |
| 03:45 ET | 1427 | 28.461 |
| 03:48 ET | 3700 | 28.395 |
| 03:50 ET | 2349 | 28.445 |
| 03:52 ET | 2300 | 28.51 |
| 03:54 ET | 2906 | 28.54 |
| 03:56 ET | 5809 | 28.595 |
| 03:57 ET | 4311 | 28.565 |
| 03:59 ET | 96750 | 28.66 |
Sep 9, 2024
DJ Denali Therapeutics Price Target Maintained With a $35.00/Share by Cantor Fitzgerald, from 11:46AM ET on Monday Sep 09, 2024 by Dow Jones
11:46AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Denali Therapeutics Inc | 4.0B | -10.0x | --- |
CRISPR Therapeutics AG | 3.8B | -14.2x | --- |
Axsome Therapeutics Inc | 4.4B | -13.3x | --- |
ADMA Biologics Inc | 4.6B | 144.2x | --- |
Apellis Pharmaceuticals Inc | 3.4B | -10.0x | --- |
TG Therapeutics Inc | 3.4B | 37.0x | --- |
Company Information
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Contact Information
- Headquarters
- 161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
- Phone
- 650-866-8548
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Vicki Sato
- President, Chief Executive Officer, Director
- Ryan Watts
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Alexander Schuth
- Chief Medical Officer
- Carole Ho
- Director
- Steven Krognes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0B |
|---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 143.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-2.85 |
Book Value | $7.45 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | 3,188.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,938.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
